Slide 1: 3Q2024 Earnings
3Q2024 Earnings November 12, 2024 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Su
Slide 3: Progress on 2H2024 Goals and Milestones
Progress on 2H2024 Goals and Milestones Goal / Milestone Timing Progress Initiation of IND enabling activities for SST3 candidate for ADPKD 3Q 2024 NDA submission for paltusotine in acromegaly 3Q2024 Raise capital to fund development of additional pipeline programs 4Q2024 Nomination of TSH candidate
Slide 4: Deep Pipeline of Transformative Drug Candidates
Deep Pipeline of Transformative Drug Candidates Program Discovery IND-Enabling Phase 1 Phase 2 Phase 3 Registrational Anticipated Milestones Acromegaly (PATHFNDR-1 and -2) Acromegaly NDA Acceptance Paltusotine (SST2 agonist) (December 2024) Carcinoid syndrome Initiation of Phase 3 (4Q2024) Congenita
Slide 5: CRN09682 is Designed to Selectively Target and Deliver Cytotoxic Payloads to SST2-Expressing Tumor Cells
CRN09682 is Designed to Selectively Target and Deliver Cytotoxic Payloads to SST2-Expressing Tumor Cells MMAE • Non-cytotoxic when linked • Highly potent when free Cleavage Site • Stable in plasma • Cleaved intracellularly Selective Nonpeptide SST2 Agonist • High affinity • High selectivity • Optimi
Slide 6: CRN09682 Is Internalized Into Tumor Cells and Releases MMAE to Trigger Microtubule Disruption and Apoptosis
CRN09682 Is Internalized Into Tumor Cells and Releases MMAE to Trigger Microtubule Disruption and Apoptosis MMAE: monomethyl auristatin E; tubulin inactivator CONFIDENTIAL CRINETICS PHARMACEUTICALS | 6
Slide 7: Financials
Financials Three months ended September 30, 2024 2023 (in millions) Revenues $ 0.0 $ 0.3 R&D Expenses 61.9 43.8 G&A Expenses 25.9 15.5 Net Loss $(76.8) $(57.5) Cash and equivalents totaled $863 million as of September 30, 2024, and approximately $1.4 billion on a pro forma basis following the publ
Slide 8: 3Q2024 Earnings
3Q2024 Earnings November 12, 2024 9